Alimera Sciences (NASDAQ:ALIM) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.07), Yahoo Finance reports. The business had revenue of $9.14 million for the quarter, compared to analyst estimates of $9.60 million.
Alimera Sciences (NASDAQ:ALIM) traded up $0.06 during mid-day trading on Thursday, hitting $1.30. 170,900 shares of the stock were exchanged, compared to its average volume of 142,872. The stock has a market capitalization of $85.74, a PE ratio of -4.19 and a beta of 1.79. The company has a quick ratio of 4.65, a current ratio of 4.84 and a debt-to-equity ratio of -0.71. Alimera Sciences has a twelve month low of $1.03 and a twelve month high of $1.72.
In other news, CEO C. Daniel Myers sold 52,900 shares of the business’s stock in a transaction dated Friday, January 19th. The shares were sold at an average price of $1.20, for a total transaction of $63,480.00. Following the completion of the sale, the chief executive officer now owns 101,511 shares of the company’s stock, valued at $121,813.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Philip Ashman sold 25,500 shares of the business’s stock in a transaction dated Friday, January 19th. The stock was sold at an average price of $1.20, for a total transaction of $30,600.00. Following the sale, the senior vice president now directly owns 12,750 shares of the company’s stock, valued at approximately $15,300. The disclosure for this sale can be found here. Insiders have sold 184,704 shares of company stock valued at $224,432 in the last three months. Corporate insiders own 14.70% of the company’s stock.
WARNING: This news story was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3231425/alimera-sciences-alim-releases-earnings-results.html.
About Alimera Sciences
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.